Key facts
- SelectION’s last known valuation is $195.0M (Jun 2023).
- It has raised $19.6M across 4 recorded rounds; the latest was Early Stage VC ($5.4M) in Sep 2025.
- Notable investors include Bay Area Biosciences Association, BioM Biotech Cluster Development, Bundesministerium für Bildung und Forschung, Global Source Ventures, Mey Capital Matrix — 6 tracked in total.
- SelectION has filed 4 Form Ds with the SEC since 2019, most recently Sep 2025 ($5.4M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for SelectION
Funding rounds
4 roundsAbout SelectION
Developer of peptide therapeutics designed to assist in the treatment of autoimmune diseases and disorders. The company's therapeutics use an ion channel technology platform to discover and develop selective peptides by functionally inhibiting and eliminating disease-associated chronically activated TEM cells without compromising the protective immune response, enabling healthcare professionals to achieve effective treatments for pain management and oncology.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2002
- Employees
- 3
- Website
- selectiontherapeutics.com/
- Ownership
- Privately Held (backing)
SelectION doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SelectION shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SelectION in its N-PORT filings yet. We sweep new filings monthly.